TCRX

1.845

12.14% -0.255

Dopo l'orario di chiusura: 1.85 0.005 +0.27%

Tscan Therapeutics Inc (TCRX)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$2.10

Aprire:

$2.1

Volume 24 ore:

339.39K

Relative Volume:

0.76

Capitalizzazione di mercato:

$113.86M

Reddito:

$21.05M

Utile/perdita netta:

$-89.22M

Rapporto P/E:

-1.0307

EPS:

-1.79

Flusso di cassa netto:

$-64.50M

1 W Prestazione:

-13.38%

1M Prestazione:

-24.07%

6M Prestazione:

-65.77%

1 anno Prestazione:

-74.38%

Intervallo 1D:

$1.84

$2.12

Intervallo di 1 settimana:

$1.84

$2.1797

Portata 52W:

$1.84

$9.69

Tscan Therapeutics Inc Stock (TCRX) Company Profile

Nome

Tscan Therapeutics Inc

Settore

Healthcare (1189)

Industria

Biotechnology (682)

Telefono

857-399-9500

Indirizzo

880 WINTER STREET, WALTHAM

Dipendente

199

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

TCRX's Discussions on Twitter

Confronta TCRX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TCRX Tscan Therapeutics Inc	1.845	113.86M	21.05M	-89.22M	-64.50M	-1.79
VRTX Vertex Pharmaceuticals Inc	483.31	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	684.87	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	622.61	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.53	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	111.56	27.34B	3.30B	-501.07M	1.03B	-2.1146

Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-05-16	Iniziato	BTIG Research	Buy
2024-05-13	Iniziato	Needham	Buy
2023-06-22	Iniziato	Wedbush	Outperform

Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie

Feb 27, 2025

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 27, 2025

How Will TScan's Cancer Therapy Pipeline Impress Investors at Major Healthcare Conference? - StockTitan

Feb 27, 2025

Feb 18, 2025

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire

Feb 18, 2025

Inside TScan's Revolutionary TCR Cell Therapy Pipeline: CEO Conference Presentation Revealed - StockTitan

Feb 18, 2025

Feb 14, 2025

abrdn plc Has $2.69 Million Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

Feb 14, 2025

Feb 10, 2025

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting (NASDAQ:TCRX) - Seeking Alpha

Feb 10, 2025

Feb 05, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - MarketBeat

Feb 05, 2025

Feb 02, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Purchased by JPMorgan Chase & Co. - Defense World

Feb 02, 2025

Jan 21, 2025

Barclays PLC Purchases 44,903 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Jan 21, 2025

Jan 17, 2025

TScan Therapeutics' SWOT analysis: innovative t-cell therapy stock faces pivotal year - MSN

Jan 17, 2025

TScan Therapeutics, Inc.'s (NASDAQ:TCRX) recent 14% pullback adds to one-year year losses, institutional owners may take drastic measures - Simply Wall St

Jan 17, 2025

Jan 11, 2025

Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks - MSN

Jan 11, 2025

Jan 10, 2025

TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World

Jan 10, 2025

Jan 07, 2025

Jane Street Group LLC Decreases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Jan 07, 2025

Jan 06, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Acquired by Barclays PLC - Defense World

Jan 06, 2025

Jan 05, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Geode Capital Management LLC - Defense World

Jan 05, 2025

Dec 31, 2024

State Street Corp Has $3.77 Million Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Dec 31, 2024

Dec 28, 2024

TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an inve - Defense World

Dec 28, 2024

Dec 27, 2024

TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Increased by Stifel Financial Corp - Defense World

Dec 27, 2024

Dec 26, 2024

TScan secures $30 million through warrant sale to Lynx1 By Investing.com - Investing.com Nigeria

Dec 26, 2024

TScan Therapeutics Refinances Existing Debt Facility with Silicon Valley Bank - Defense World

Dec 26, 2024

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium - The Manila Times

Dec 26, 2024

TScan Therapeutics (TCRX) Secures $30M Premium-Priced Financing, Extends Cash Runway to 2027 - StockTitan

Dec 26, 2024

Dec 25, 2024

With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing - Yahoo Finance

Dec 25, 2024

Dec 24, 2024

Recent Research Analysts’ Ratings Updates for TScan Therapeutics (TCRX) - Defense World

Dec 24, 2024

TScan Therapeutics’ (TCRX) “Outperform” Rating Reaffirmed at Wedbush - Defense World

Dec 24, 2024

Dec 23, 2024

Wedbush Reiterates "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat

Dec 23, 2024

TScan Therapeutics Secures $52.5M Loan from SVB - TipRanks

Dec 23, 2024

TScan Therapeutics Refinances Existing Convertible Debt - GlobeNewswire

Dec 23, 2024

TScan Therapeutics Secures Major $52.5M Financing Deal to Extend Cash Runway Through 2026 - StockTitan

Dec 23, 2024

Dec 22, 2024

XTX Topco Ltd Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Dec 22, 2024

Dec 17, 2024

2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart

Dec 17, 2024